tiprankstipranks
Blueprint Medicines to regain global rights to gavreto from Roche
The Fly

Blueprint Medicines to regain global rights to gavreto from Roche

Blueprint Medicines (BPMC) announced it will regain global commercialization and development rights to gavreto, excluding Greater China, following a decision by Roche (RHHBY) to discontinue the collaboration agreement between the companies for gavreto for strategic reasons. Under the terms of the agreement, the termination will be effective 12 months from the notification date of February 22, 2023. During the transition period, Blueprint Medicines and Roche are mutually committed to ensuring a smooth transition process with no anticipated interruptions or changes to patient access. In addition, the company will explore options to advance and simplify the continued global commercialization and development of gavreto. Since the initiation of the collaboration with Roche in July 2020, Blueprint Medicines has benefited from approximately $1B between upfront and milestone payments and from cost-sharing the commercialization and development of gavreto. The company anticipates no impact to its 2023 revenue guidance, which includes $40M-$50M in collaboration revenues from existing collaborations, or its anticipated operating expenses in 2023. In addition, the company continues to expect that its existing cash, cash equivalents and investments, together with anticipated future product revenues, will provide sufficient capital to enable the company to achieve a self-sustainable financial profile.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on BPMC:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles